

**AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31 MARCH 2011**

(Rs. in lacs)

Sr. No.	Particulars	Year ended (Audited)	
		31 March 2011	31 March 2010
1	a) Net Sales / Income from operations	38,940.74	34,942.03
	b) Other operating income	193.65	97.84
	Total ( 1 )	39,134.39	35,039.87
2	Expenditure		
	a) ( increase ) / decrease in stock in trade	(2,975.11)	(794.94)
	b) Consumption of raw materials	26,962.16	24,082.48
	c) Purchase of traded goods	145.27	679.30
	d) Employees cost	1,641.58	1,125.07
	e) Depreciation	2,376.28	1,001.12
	f) Other expenditure	6,402.05	5,996.51
	Total ( 2 )	34,552.23	32,089.54
3	Profit from operations before other income, interest and exceptional items ( 1-2 )	4,582.16	2,950.33
4	Other income	1.80	1.80
5	Profit before interest and exceptional items (3+4)	4,583.96	2,952.13
6	Interest	3,679.65	1,486.74
7	Profit after interest but before exceptional items (5-6)	904.31	1,465.39
8	Exceptional items	--	--
9	Profit from ordinary activities before tax (7+8)	904.31	1,465.39
10	Tax Expenses	286.39	463.80
11	Net Profit from ordinary activities after tax (9-10)	617.92	1,001.59
12	Extraordinary Item (net of tax expense)	--	--
13	Net Profit for the period (11-12)	617.92	1,001.59
14	Paid-up equity share capital (Face value Rs.10/- Per Share)	2,571.67	2,271.67
15	Reserves excluding revaluation reserves	13,952.15	11,624.23
16	Earning per share (not annualized)		
	- Basic	2.52	4.69
	- Diluted	2.52	4.68
	- Cash	12.69	10.38
17	Public shareholding		
	- No of shares	1,17,76,611	1,02,76,611
	- % age	45.79	45.24
18	Promoters and promoter group shareholding		
	a) Pledged/encumbered		
	- Number of shares	--	4,00,000
	- %age of the total promoters' shareholding	--	3.22
	- % age of the total shareholding	--	1.76
	b) Non-encumbered		
	- Number of shares	1,39,40,053	1,20,40,053
	- %age of the total promoters' shareholding	100	96.78
	- % age of the total shareholding	54.21	53.00

**Segment wise Revenue, Results and Capital Employed, under clause 41 of the Listing Agreement**

(Rs. in Lacs)

Sr. No	Particulars	Year ended (Audited)	
		31 March 2011	31 March 2010
1	Segment Revenue (Net sales/income)		
	- Chemicals	28,851.92	23,166.83
	- Drugs	13,870.37	11,676.92
	- Unallocated	245.36	196.12
	Total	42,967.65	35,039.87
	Less : Inter segment revenue	3,833.26	--
	Net sales/income from operations	39,134.39	35,039.87
2	Segment Results		
	Profit/(loss) before tax and interest from each segment)		
	- Chemicals	2,285.74	1,396.21
	- Drugs	2,171.15	1,441.86
	Total	4,456.89	2,838.07
	Less :		
	Interest	3,679.65	1,486.74
	Other un-allocable expenditure net off un-allocable income	(127.07)	(114.06)
	Total Profit before tax & Extraordinary Items	904.31	1,465.39
3	Capital Employed		
	(Segment assets - Segment liabilities)		
	- Chemicals	28,173.95	25,770.21
	- Drugs	12,699.81	13,218.56
	- Unallocated including capital work in progress	11,775.81	3,458.39
	Total	52,649.57	42,447.16

## STATEMENT OF ASSETS AND LIABILITIES

(Rs. in Lacs)

S.NO.	PARTICULARS	As at	
		31 March 2011	31 March 2010
1	Shareholder's Funds		
	(a) I Capital	3,071.67	2,771.67
	II Convertible Warrants	210.00	420.00
	(b) Reserves and Surplus	13,952.15	11,624.23
2	Loan Funds	34,410.18	26,912.08
3	Deferred Tax Liabilities	1,005.57	719.17
	Total	52,649.57	42,447.15
1	Fixed Assets	41,272.45	37,339.43
2	Current Assets, Loans and Advances		
	(a) Inventories	9,955.62	6,686.54
	(b) Sundry Debtors	3,813.13	3,010.69
	(c) Cash and Bank Balances	1,993.93	660.22
	(d) Loans and Advances	3,951.19	3,124.78
	Sub Total	19,713.87	13,482.23
3	Less: Current Liabilities and Provisions		
	(a) Current Liabilities	8,255.87	8,247.54
	(b) Provisions	80.88	126.97
	Sub Total	8,336.75	8,374.51
	Net Current Assets	11,377.12	5,107.72
	Total	52,649.57	42,447.15

### Notes:

- The progress on the Implementation of multi purpose PPIs plant (anti-ulcerant API's) and other pharmaceutical intermediate products with a CAPAX of Rs 130 crore is on schedule and has invested Rs 61.77 crore upto 31 March 2011 on the said project.
- The company has issued 30 lac equity shares during the year.
- Status of Investor's complaints for the quarter ended 31 March 2011 is as under:

Complaints at the beginning of quarter	Complaints received during the quarter	Complaints resolved	Complaints pending
Nil	Nil	Nil	Nil

- Tax expenses include current tax and deferred tax
- The figures of previous year have been regrouped/ rearranged wherever necessary.
- The above results have been reviewed by the Audit & Risk Management Committee and were considered and approved by the Board of the Directors at their meeting held on 21 May 2011.

**By order of the Board**

For IOL Chemicals and Pharmaceuticals Limited

Place: New Delhi  
Date: 21 May 2011

Sd/-  
(Varinder Gupta)  
Chairman and Managing Director